Scalable, flexible manufacture: simplifying cell & gene therapy production

Many of the life sciences trends driving innovation today were here pre-COVID- the pandemic was merely an accelerant that opened numerous ‘proof of concept’ opportunities for tools, processes, and facilities alike.

Now, more than ever, speed and flexibility are at the forefront of current life sciences trends. Quick and effective implementation of solutions that benefit the health and well-being of the global population is imperative. Innovations like rapidly deployable and adaptive facilities enable companies to pivot and adapt to market needs with precision and ease. 

In this webinar, we will discuss how facility design and project delivery are changing to keep up with the rapidly evolving life sciences industry, and what the future of flexible manufacturing looks like.Drawing on experience from over 300+ advanced therapy projects, we will discuss practical tips and design solutions showing the benefits of these facilities from both a CGMP and financial perspective.

• How cell & gene therapy companies can scale strategically as their pipeline products advance through the development process
• Design & construction considerations to improve commercial success
• Learn about how to meet the demanding expectations of risk, quality, and performance with a set of curated best practices
• Explore modular & podular facility options and configurations at different biomanufacturing scales
• Learn how to quantify your resource needs as you scale out or pivot modalities
• Create customized metrics to help right-size support spaces

JP Bornholdt AIA PE LEED AP

CRB

JP Bornholdt is the Director of Global SlateXpace Operations at CRB. He creates pre-eminent solutions for the life science industry by working with project teams to apply innovative and disruptive approaches such as flexible design strategies, scalable turn-key technologies, modular, offsite fabricated, and integrated project deliveries. Licensed as both an architect and engineer, his expert knowledge of multiple disciplines provides a strong basis for integrated facility design and construction.

Niranjan Kulkarni PhD

CRB

Niranjan is the senior director of CRB’s consulting group. He holds a doctorate and master’s degree in industrial and systems engineering from Binghamton University. He is also a certified Lean Six Sigma Master Black Belt. Niranjan has over 15 years of experience in business process and data modeling, operations and process simulations, process improvements, layout optimizations and supply chain management. He has worked with the pharmaceutical, biotech, food, chemical, semiconductor, electronics assembly and packaging, manufacturing and financial industries.

Carol Houts

Vice President of Quality and Business Strategy, Germfree

Carol Houts is the Vice President of Quality and Business Strategy for Germfree, an offsite clean room construction company that provides facility solutions for biopharmaceutical applications. Carol is an executive with over 25 years’ experience in pharmaceutical, and biologics product development, quality, regulatory affairs and clinical research. Carol has worked intensively to have constructive and cooperative interactions with the FDA and other global regulatory agencies through formal meetings, regulatory submissions, inspections and compliance remediation projects.

Prior to joining Germfree, Carol has worked extensively to build companies organizational and service capabilities to increase revenue and sustain long-term growth. Carol has led business development activities to achieve funding, and developed business plans for demonstrating investment opportunities.

Watch now

SPEAKERS

JP Bornholdt AIA PE LEED AP

CRB

Niranjan Kulkarni PhD

CRB

Carol Houts

Vice President of Quality and Business Strategy, Germfree

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 73

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 44

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 38

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 37

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 36

Days

Register